Clinical Trials for Ovarian Cancer

A Phase 1 Basket Study Evaluating the Safety and Feasibility of T-Plex, Autologous Customized T Cell Receptor-Engineered T Cells Targeting Multiple Peptide/HLA Antigens in Participants With Antigen-positive Locally Advanced (Unresectable) or Metastatic Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls adults with unresectable or metastatic solid tumors expressing MAGE-A1, MAGE-A4, MAGE-C2, PRAME, or HPV16 antigens and specified HLA types, who have exhausted standard treatments. Participants receive autologous TCR-engineered T cells (TCR-T) targeting these antigens, as monotherapy or in combination, following lymphodepleting chemotherapy.

ClinicalTrials.gov ID: NCT05973487

A Phase I/II Study of VLS-1488 (an Oral KIF18A Inhibitor) in Subjects With Advanced Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with advanced solid tumors—such as high grade serous ovarian, squamous NSCLC, triple negative breast, gastric, colorectal, esophageal, bladder, head and neck, and select gynecologic cancers—who have progressed on standard therapies receive oral VLS-1488, a selective inhibitor of the mitotic kinesin KIF18A, given in 28-day cycles. Patients with active CNS metastases, prior KIF18A inhibitor exposure, or MSI-H/dMMR tumors are excluded.

ClinicalTrials.gov ID: NCT05902988

A Phase 1, Open-label, Multi-center Study of the Safety, Tolerability, and Efficacy of IPH4502 as a Single Agent in Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls adults with unresectable, locally advanced or metastatic solid tumors expressing Nectin-4 who have progressed after or are ineligible for standard systemic therapy, excluding those with brain metastases or serious comorbidities. Patients receive IPH4502, a novel antibody-drug conjugate targeting Nectin-4 with an exatecan payload, administered as monotherapy.

ClinicalTrials.gov ID: NCT06781983

Phase Ib/IIa Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Eligible patients are adults with advanced, refractory solid tumors (including soft-tissue sarcoma, triple-negative breast cancer, NSCLC, cervical cancer, ovarian cancer, or KRAS-mutant pancreatic ductal adenocarcinoma), who have not previously received anthracyclines. The trial investigates Spedox-6, a novel human serum albumin-encapsulated doxorubicin formulation designed to enhance tumor delivery and reduce cardiotoxicity, given IV every 21 days at escalating doses (with filgrastim support at higher doses).

ClinicalTrials.gov ID: NCT07064018

A Phase I/II, Dose-escalation and Dose-optimization Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of MT-4561 in Patients With Various Advanced Solid Tumors and to Evaluate Effect of MT-4561 on Pharmacokinetics of Oral Midazolam

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls adults with advanced solid tumors—including HNSCC, NSCLC, GI, GU, gynecologic, sarcoma, neuroendocrine, and NUT carcinoma—who have measurable disease and good performance status, to evaluate the intravenous BRD4 degrader MT-4561 administered weekly. MT-4561 is a novel agent targeting BRD4 for ubiquitin-mediated degradation and is being assessed primarily for safety and initial efficacy in this biomarker-unselected population.

ClinicalTrials.gov ID: NCT06943521

A Phase 1a/1b, Multicenter, Open-label, Dose Escalation/Expansion, Multiple-dose Study to Evaluate the Safety and Activity of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Enrolling adults with locally advanced or metastatic epithelial cancers (including multiple breast cancer subtypes, NSCLC, cervical, prostate, pancreatic, head and neck, endometrial, ovarian, gastric/GEJ, or urothelial carcinomas) who have progressed after ≥2 prior therapies and lack standard options, this study delivers IV DR-0202, a bispecific antibody targeting CLEC7A on myeloid cells and a tumor-associated antigen, aiming to activate myeloid-driven phagocytosis and antitumor immunity.

ClinicalTrials.gov ID: NCT06999187

A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BL-M17D1 in Subjects With HER2-Expressing or HER2-Mutant Advanced or Metastatic Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls adults with unresectable, locally advanced, or metastatic HER2-positive or HER2-mutant solid tumors (including but not limited to breast, gastric/GEJ, NSCLC, endometrial, ovarian, and urothelial cancers) who have progressed on or are not candidates for standard therapy. Patients receive BL-M17D1, an investigational HER2-targeted antibody-drug conjugate, given intravenously on Days 1 and 8 of a 21-day cycle.

ClinicalTrials.gov ID: NCT06714617

A Phase 1/2, Open-label, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ETX-636, a Pan-mutant-selective PI3Kα Inhibitor, as Monotherapy and in Combination With Other Anticancer Therapies in Participants With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls adults with advanced solid tumors harboring activating PIK3CA mutations who have progressed after standard therapy, including a cohort specifically for HR+/HER2- advanced breast cancer with prior CDK4/6 inhibitor and anti-estrogen exposure. Patients receive ETX-636, an oral, mutant-selective PI3Kα inhibitor and degrader, either as monotherapy or combined with fulvestrant.

ClinicalTrials.gov ID: NCT06993844

An Open-Label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of XL309 (ISM3091) as Single-Agent and Combination Therapy in Patients With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls adults with advanced solid tumors harboring deleterious or suspected deleterious BRCA1/2 or other homologous recombination repair mutations—such as HER2-negative BRCA-mutant breast cancer, high-grade serous ovarian or fallopian tube cancer, metastatic castration-resistant prostate cancer, and pancreatic cancer—who have progressed on, are intolerant to, or are ineligible for standard therapies (including PARP inhibitors). Patients receive the investigational oral USP1 inhibitor XL309, which disrupts DNA repair, as monotherapy or in combination with olaparib.

ClinicalTrials.gov ID: NCT05932862

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial enrolls adults with advanced or metastatic hepatocellular, renal cell, breast, ovarian/fallopian, or endometrial/primary peritoneal cancers involving the abdomen or thorax who have progressed on or are intolerant to standard therapies, and evaluates safety of Tumor Treating Fields (TTF) in combination with either cabozantinib (a multi-kinase inhibitor targeting MET, VEGFR, and AXL) or nab-paclitaxel plus atezolizumab (a PD-L1 inhibitor).

ClinicalTrials.gov ID: NCT05092373